Clinical Trial News and Research

RSS

Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for patent application U.S. 13/825,018 entitled, "Estimation of Distances and Size of Lesions in the Colon with an Imaging Capsule."

27 Apr 2015

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories").

27 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.

27 Apr 2015

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share.

27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

New study suggests that exercise type may be less important in fight against obesity

Medical experts widely recommended a combined program of diet and fitness to fight obesity. But when it comes to the type of exercise most effective a reducing weight and body mass—strength training, endurance exercise or a combination of both—opinions vary widely on which exercise regimen is best.

27 Apr 2015

Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

A new clinical trial is testing the feasibility and efficiency of a doctor in New York City remotely performing long-distance, tele-robotic ultrasound exams over the Internet on patients in Chicago.

27 Apr 2015

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival.

27 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread.

25 Apr 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.

25 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Interventional treatments provide good functional outcomes for patients with lower-grade brain AVMs

Interventional treatments--especially surgery--provide good functional outcomes and a high cure rate for patients with lower-grade arteriovenous malformations (AVMs) of the brain, reports the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

24 Apr 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

24 Apr 2015

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S.

23 Apr 2015

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

23 Apr 2015

Clinical Trial News and Research

Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Neuronetics completes Series F Financing Round

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

OncoGenex terminates agreement with Teva, regains rights to custirsen

New study suggests that exercise type may be less important in fight against obesity

Study explores how NYC doctor can perform tele-robotic ultrasound over the Internet on patients in Chicago

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Interventional treatments provide good functional outcomes for patients with lower-grade brain AVMs

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery